7
Oct 21 (Reuters) – Actinogen Medical Ltd: * NARROW GUIDANCE FOR TOPLINE RESULTS FOR XANAMIA PHASE 2B/3 ALZHEIMER'S DISEASE CLINICAL TRIAL TO MID-NOV THIS YEAR Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
